Max Schlaak
Papers
1
Total Citations
45
H-Index
1
About
Max Schlaak is a leading clinical researcher at the intersection of radiation oncology and immunotherapy, with a primary focus on optimizing treatment for melanoma patients with brain metastases. His most cited work, "Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment" (2018, 45 citations), addresses the critical question of how to safely combine stereotactic radiosurgery with immune checkpoint inhibitors. Schlaak’s research provides vital insights into imaging findings, acute toxicity, and local control outcomes when these two powerful modalities are used concurrently—a topic of intense interest as combination therapies become standard of care. By demonstrating the feasibility and safety of this approach, his work has helped shape clinical protocols for managing melanoma brain metastases, a historically challenging patient population. Schlaak’s contributions are particularly notable for bridging the gap between preclinical promise and real-world evidence, offering practical guidance to oncologists navigating the complexities of combined radio-immunotherapy. His findings continue to inform ongoing trials and clinical decision-making, underscoring his role as a key voice in the evolving landscape of neuro-oncology and immuno-radiotherapy.
Research Focus
Key Achievements
Top Papers
- 1